Cargando…

1082. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial Infections: A Multicenter Evaluation

BACKGROUND: Nontuberculous mycobacteria (NTM) are resistant to numerous antibiotics and lead to significant morbidity and mortality. Omadacycline (OMC) is an aminomethylcycline antibiotic that is Food and Drug Administration-approved for acute bacterial skin and skin structure infections and communi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morrisette, Taylor, Alosaimy, Sara, Lagnf, Abdalhamid M, Philley, Julie V, Sigler, Carly, Butt, Saira, Kaip, Emily A, MacDougall, Conan, Mejia-Chew, Carlos, Bouchard, Jeannette, Frens, Jeremy J, Gore, Tristan, Hamad, Yasir, Howard, Catessa, Barger, Melissa, Gabriela Cabanilla, M, Ong, Aaron, Veve, Michael P, Webb, Andrew J, Stevens, Ryan W, Cohen, Keira A, Rybak, Michael J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644900/ http://dx.doi.org/10.1093/ofid/ofab466.1276

Ejemplares similares

1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation
por: Morrisette, Taylor, et al.
Publicado: (2020)

Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections
por: Morrisette, Taylor, et al.
Publicado: (2021)

Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens
por: Morrisette, Taylor, et al.
Publicado: (2022)

Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes
por: El Ghali, Amer, et al.
Publicado: (2023)

1422. A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections
por: Ghali, Amer El, et al.
Publicado: (2022)

Impact of Ceftolozane–Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections
por: Holger, Dana J., et al.
Publicado: (2022)

144. Antifungal Use Trends in Hospitalized Adults in the United States, 2016-2020
por: Kaip, Emily A, et al.
Publicado: (2021)

Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis
por: Alosaimy, Sara, et al.
Publicado: (2020)

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
por: Rebold, Nicholas, et al.
Publicado: (2021)

Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure
por: Rebold, Nicholas, et al.
Publicado: (2023)

Clinical Characteristics Associated with Bacterial Bloodstream Coinfection in COVID-19
por: Rebold, Nicholas, et al.
Publicado: (2022)

COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options
por: Rebold, Nicholas, et al.
Publicado: (2021)

1577. Real-World, Multicenter Experience with Eravacycline for Various Infections
por: Alosaimy, Sara, et al.
Publicado: (2020)

Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant Staphylococcus aureus Bacteremia: STAPH Study
por: Alosaimy, Sara, et al.
Publicado: (2021)

Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections
por: Alosaimy, Sara, et al.
Publicado: (2020)

The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA—Salvaging the Gold Standards with Combination Therapy
por: Morrisette, Taylor, et al.
Publicado: (2020)

1575. Predictors of Negative Clinical Outcomes among Patients treated with Meropenem-Vaborbactam for Serious Gram-Negative Bacterial Infections: Impact of Delayed Appropriate Antibiotic Selection
por: Alosaimy, Sara, et al.
Publicado: (2020)

Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii
por: Alosaimy, Sara, et al.
Publicado: (2022)

1297. Design and Testing of an Interactive Module for Improving Understanding and Application of Institutional Antibiograms
por: MacDougall, Conan
Publicado: (2022)

1227. Development of a Clinical Prediction Model for Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Jorgensen, Sarah, et al.
Publicado: (2018)

1061. Comparison of the Acute Physiology and Chronic Health Evaluation (APACHE) II Score and the Pitt Bacteremia Score to Predict Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Jorgensen, Sarah, et al.
Publicado: (2018)

200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation
por: Alosaimy, Sara, et al.
Publicado: (2019)

Risk Factors and Outcomes for Bloodstream Infections (BSI) Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Rybak, Michael J, et al.
Publicado: (2017)

Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis
por: Claeys, Kimberly C., et al.
Publicado: (2017)

2254. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
por: Alosaimy, Sara, et al.
Publicado: (2021)

Omadacycline: a novel aminomethylcycline
por: Burgos, Rodrigo M, et al.
Publicado: (2019)

Omadacycline: A Modernized Tetracycline
por: Gallagher, Jason C
Publicado: (2019)

Microbiology and Preclinical Review of Omadacycline
por: Karlowsky, James A, et al.
Publicado: (2019)

Investigating the immunomodulatory activities of omadacycline
por: Bryant, Amy E, et al.
Publicado: (2022)

Acute Bacterial Skin and Skin Structure Infections Treated with Intravenous Antibiotics in the Emergency Department or Observational Unit: Experience at the Detroit Medical Center
por: Claeys, Kimberly C., et al.
Publicado: (2015)

2103. Comparison of Antibiograms Across Solid Organ Transplant Services Within a Medical Center
por: Kim, Annie, et al.
Publicado: (2022)

Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics
por: Trang, M., et al.
Publicado: (2023)

1073. Predictors of Vancomycin Switch or Escalation in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infection
por: Lagnf, Abdalhamid M, et al.
Publicado: (2018)

1596. Impact of Vancomycin Area Under Curve on Persistent Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)
por: Alosaimy, Sara, et al.
Publicado: (2019)

442. Risk Score for Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam
por: Jorgensen, Sarah C. J., et al.
Publicado: (2020)

Development of a Risk-Scoring Tool to Determine Appropriate Level of Care in Acute Bacterial Skin and Skin Structure Infections in an Acute Healthcare Setting
por: Claeys, Kimberly C., et al.
Publicado: (2018)

DoD2007: 1082 molecular biology databases
por: Babu, Padavala Ajay, et al.
Publicado: (2007)

PReS13-SPK-1082: Catastrophic antiphospholipid syndrome
por: Cervera, R
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_52vhv1gpat1lr13ttmucl2q9qo